NP10679

NP10679 is a selective, pH-dependent inhibitor of the GluN2B subunit of the N-methyl-D-aspartate (NMDA) receptor. It acts as a context-dependent and subunit-selective negative allosteric modulator, showing greater potency at acidic extracellular pH levels (such as those found in ischemic brain tissue) than at physiological pH. This property allows for targeted inhibition in injured or diseased brain regions while minimizing effects on healthy tissue, potentially reducing adverse side effects associated with non-selective NMDA antagonists. NP10679 has demonstrated high oral bioavailability, good brain penetration, and was well-tolerated in Phase 1 clinical trials with a half-life suitable for once-daily dosing. The drug is being developed primarily for acute neurological conditions such as ischemic stroke and aneurysmal subarachnoid hemorrhage (SAH), but may also have potential applications in other central nervous system disorders including severe pain and treatment-resistant depression[1][2][3][5][6][7][8].

Other names

NP-10679NP10679NP 10679